Asia Autoimmune and inflammatory therapies
Autoimmune drugs: calming an immune system that attacks the body's own tissues.
8Tracked assets
6Approved
How this track works
In autoimmune and inflammatory diseases such as psoriasis, atopic dermatitis, lupus and rheumatoid arthritis, the immune system attacks the body's own tissue. Older drugs damp down immunity broadly; newer ones block a single signal, such as JAK or TYK2 inside cells, or IL-4R, IL-17 and BAFF/APRIL outside them. China has moved fast: several Chinese-originated antibodies and JAK inhibitors are now approved at home, and global companies are licensing them for the rest of the world.
Development stage
Approved6 6
Phase 32 2
Origin country / region
Japan2 2
China6 6
Assets
| Rank | Asset | INN | Originator | Country | Targets | Mechanism | Highest stage | Indication | Trial IDs | Overseas rights holder | Deal date | Upfront | Total ceiling | Latest event | Latest event date | Sources | Source date |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Peficitinib (ASP015K; Smyraf) | peficitinib | Astellas Pharma Inc. | Japan | JAK family | Oral pan-JAK inhibitor | Approved — Japan (2019-03) | Rheumatoid arthritis | NCT02308163 | NCT02305849 | Menarini Asia-Pacific — Taiwan; option for select Southeast Asian markets | 2023-09-13 (announcement) | Not disclosed | €5.5 million (upfront + milestones; royalties additional) | Menarini announces Taiwan licensing agreement, with option for select Southeast Asian markets | 2023-09-13 | 1 2 3 4 5 | 2023-09-13 |
| 2 | Delgocitinib (JTE-052; Corectim / Anzupgo) | delgocitinib | Japan Tobacco Inc. | Japan | JAK family | Topical pan-JAK inhibitor | Approved — Japan (2020-01); US (2025-07) | Atopic dermatitis (Japan ointment); chronic hand eczema (US cream) | NCT05355818 | NCT06004050 | LEO Pharma — topical dermatology worldwide excluding Japan | 2014-11 | Not disclosed | Not disclosed | FDA approves Anzupgo cream for adult moderate-to-severe chronic hand eczema | 2025-07-23 | 1 2 3 4 5 6 | 2025-07-23 |
| 3 | Telitacicept (RC18; Taiai) | telitacicept | RemeGen Co., Ltd. | China | BAFF (BLyS); APRIL | TACI-Fc fusion protein inhibiting B-cell survival signals | Approved — China (2021-03; conditional); full approval 2023-11 | Systemic lupus erythematosus; rheumatoid arthritis; generalized myasthenia gravis | NCT03016013 | NCT05737160 | Vor Biopharma Inc. (Vor Bio) — worldwide excluding Greater China | 2025-06-25 | US$45 million cash + US$80 million warrants (US$125 million initial consideration) | US$125 million initial consideration + up to US$4,105 million milestones; royalties additional | RemeGen announces exclusive ex-Greater China license to Vor Bio | 2025-06-25 | 1 2 3 4 5 | 2025-06-25 |
| 4 | Vunakizumab (SHR-1314; Andajing) | vunakizumab | Jiangsu Hengrui Pharmaceuticals Co., Ltd. / Suzhou Suncadia Biopharmaceuticals Co., Ltd. | China | IL-17A | Humanized monoclonal antibody neutralizing IL-17A | Approved — China (2024-08) | Moderate-to-severe plaque psoriasis; active ankylosing spondylitis | NCT04839016 | None reported | — | — | — | Suzhou Industrial Park reports approval for active ankylosing spondylitis | 2025-05-07 | 1 2 3 4 | 2025-05-07 |
| 5 | Stapokibart (CM310; Kangyueda) | stapokibart | Keymed Biosciences Inc. | China | IL-4Rα | Humanized monoclonal antibody blocking IL-4 and IL-13 signaling via IL-4Rα | Approved — China (2024-09) | Atopic dermatitis; chronic rhinosinusitis with nasal polyps; seasonal allergic rhinitis | NCT05265923 | None reported | — | — | — | Company annual results report three approved stapokibart indications | 2025-03-26 | 1 2 3 4 | 2025-03-26 |
| 6 | Ivarmacitinib (SHR0302; Aisuda) | ivarmacitinib | Jiangsu Hengrui Pharmaceuticals Co., Ltd. / Reistone Biopharma | China | JAK1 | Selective JAK1 small-molecule inhibitor; oral and topical development | Approved — China (2025-03) | Active ankylosing spondylitis; rheumatoid arthritis; atopic dermatitis; severe alopecia areata | NCT04481139 | NCT05470413 | Arcutis — topical dermatology in US, Japan, UK, EU and Canada; ARQ-255 development halted | 2018-01 (option agreement); 2019-12 (license exercised) | US$0.4 million upfront + US$1.5 million option exercise | Up to US$20.5 million development/regulatory + US$200 million sales milestones; initial payments and royalties additional | Hengrui announces China approval for severe alopecia areata | 2025-06-30 | 1 2 3 4 5 6 | 2025-06-30 |
| 7 | Soficitinib (ICP-332) | soficitinib | InnoCare Pharma Limited / Beijing InnoCare Pharma Tech Co., Ltd. | China | TYK2 (JH1) | Oral ATP-site TYK2 inhibitor | Phase 3 — China (2024-11) | Moderate-to-severe atopic dermatitis; other inflammatory skin diseases in earlier-stage trials | NCT06775860 | None reported | — | — | — | Company Q3 results report primary endpoints met in atopic dermatitis Phase 3 | 2026-10-26 | 1 2 3 4 | 2026-10-26 |
| 8 | Fadeucravacitinib (ICP-488) | fadeucravacitinib | InnoCare Pharma Limited / Beijing InnoCare Pharma Tech Co., Ltd. | China | TYK2 (JH2) | Oral allosteric TYK2 inhibitor | Phase 3 — China (2025-03) | Moderate-to-severe plaque psoriasis; cutaneous lupus and Sjögren syndrome in Phase 2 | NCT06842199 | None reported | — | — | — | Company Q3 results report primary endpoints met in psoriasis Phase 3 | 2026-10-26 | 1 2 3 4 | 2026-10-26 |